Skip to main content
. 2022 Apr 23;23(9):4694. doi: 10.3390/ijms23094694

Figure 4.

Figure 4

HSP90 inhibitor treatment for leukemia (such as FLT3). By binding of the HsP90 inhibitor to the ATP/ADP pocket of Hsp90, the equilibrium state of Hsp90 becomes ADP dominant. This inhibits the function of chaperone complexes containing client proteins and promotes the degradation of client proteins.